2024 Highlights
Montefiore Einstein Cardiology
In 2024, Montefiore Einstein Cardiology advanced its leadership in cardiac care and research, making groundbreaking strides in heart transplantation, structural valve interventions and arrhythmia management, while also expanding its state-of-the-art imaging program. This commitment to innovation, alongside significant contributions to scientific research and global education, underscores Montefiore Einstein's dedication to providing the highest quality of care.
DATA & STATISTICS
2024 by the numbers
9.9%
HTx 1-year survival
4,092
Cardiac arrythmias
6,964
Diagnostic, Interventional and Structural Heart procedures
57,275
Imaging
INNOVATIONS AND ACHIEVEMENTS
Pioneering the future of treatment and care
TEAM NEWS
Leadership Achievement and Roles
Mario J Garcia, MD, FACC, FASE
Elected next U.S. vice chair for ACC Latin America, beginning in 2026. He will transition to U.S. co-chair for 2028 and 2029.
Member of the National Board of Echocardiography
Editor-in-Chief of Current Cardiovascular Imaging Reports
Luigi Di Biase, MD, PhD, FHRS, FESC, FACC
Co Chair, Pulsed Field Ablation (PFA) Registry Platform and Member of the Board of Trustees of the Heart Rhythm Society
Member of the HRA (Heart Rhythm Advocacy)
Executive Editor — EP Europace
Co Chair Epicardial ventricular arrhythmia ablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and Heart Rhythm Society, Asian Pacific, Latin American and Canadian Heart Rhythm Societies
Editor in Chief — Arrhythmia Academy
Anna E. Bortnick MD, PhD, MSc, FAHA, FACC, FSCAI
Chair of the ACC Interventional Leadership Section Council; elected as a Governor for the New York State Chapter of the ACC (NYACC) for the 2027–2030 term.
Mohamed Azeem Latib, MD
Co-Director of Euro PCR Innovation Day; Transcatheter Interventions Online
Program Development Committee of Euro PCR, London Valves, TCT, New York Valves
Associate Editor of Structural Heart Journal
Editor-in-Chief of Cardiac Interventions Today
Global PI of Envision IDE, MAGICAL-ISR, MAGICAL-SV, PREVAIL, PARADIGM, PATHFINDER, TRINITY PIVOTAL
Leandro N. Slipczuk Bustamante, MD, PhD, FACC
Editor-in-Chief of Progress in Cardiovascular Diseases
Daniel Goldstein, MD
Chair, ISHLT IMACS Registry, largest durable LVAD database in the world
Stephen J. Forest, MD
Chair of Lung Policy and Operations Committee, New York Cardiothoracic Transplant Consortium
Updates and additions to our world-renowned faculty
Michael Fattouh, MD
Cardiovascular Disease
Saul A. Rios Herrera, MD
Interventional Cardiology
Andrea Scotti, MD
Interventional Cardiology
Yumiko Kanei, MD
Cardiovascular Disease
Adaya Weissler-Snir, MD
Clinical Cardiac Electrophysiology
Clinical Trials
Advancing care through clinical trials
We participated in over 30 clinical trials in 2024, spanning from novel drugs through advanced devices for the treatment of heart failure, valvular heart disease and arrhythmias. Our investigators performed several first-in-human procedures that sought to offer better treatment options for patients with heart disease.
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE trial)
Carlos Rodriguez, MD
The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM)
Azeem Latib, MD
Maday Gonzalez, MD
TRISCEND II Pivotal Trial - Edwards Lifesciences EVOQUE Valve for Severe TR
Azeem Latib, MD
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR (PROGRESS)
Edwin Ho, MD
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. (APOLLO)
Azeem Latib, MD
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure
Snehal Patel, MD
A Randomized, Sham-controlled, Blinded (Patient and Evaluators) Feasibility Trial of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW II)
Sandhya Murthy, MD
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Yogita Rochlani, MD
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Leandro N. Slipczuk Bustamante, MD
Post-Market Real World Outcomes in WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device
Luigi Di Biase, MD
Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System (AdmIRE)
Luigi Di Biase
Growing our footprint with new state-of-the-art facilities
We expanded our footprint, opening Montefiore Einstein Advanced Care—Westchester and new outpatient clinics at White Plains Hospital, Wakefield Campus and Montefiore Einstein Heart Failure Center at Nyack Hospital. We are also finalizing plans for a comprehensive heart failure initiative, which will include specialty clinics for amyloid, sarcoid, hypertrophic cardiomyopathy and pulmonary hypertension, cardiac intensive care consultations at Nyack Hospital and a new catheterization laboratory. We have expanded the Montefiore Einstein Structural Heart Program to White Plains Hospital. These initiatives mark a major step toward advancing Montefiore Einstein's footprint and heart failure expertise in New York’s Hudson Valley region.
Patient referrals
At Montefiore Einstein Cardiology, we know that providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.
Contact us
Delia Osborne
Assistant Director
dosborne@montefiore.org